TITLE

Sulphonylurea monotherapy: Increased mortality and CV risk when compared with metformin?

PUB. DATE
December 2011
SOURCE
Diabetes Digest;2011, Vol. 10 Issue 4, p235
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the use of sulphonylurea (SU) monotherapy and metformin for people with type 2 diabetes wherein SU increases mortality and cardiovascular (CV) risk compared with metformin.
ACCESSION #
84602849

 

Related Articles

  • Most SUs increase mortality compared with metformin.  // Diabetes Digest;2011, Vol. 10 Issue 4, p235 

    The article presents a study on the use of metformin and sulphonylureas (SUs) as treatment for people with sulphonylureas (SUs and associated mortality outcomes, in which study reveals that most SU monotheraphy increases mortality and cardiovascular (CV) risk.

  • Perspective: General practice. Gadsby, Roger // Diabetes & Primary Care;2013, Vol. 15 Issue 6, p290 

    The author comments on a study which reveals the risks for cardiovascular disease (CVD) associated with the use of the glucose-lowering agent sulphonylurea.

  • Perspective: Prescribing advisors. Newland-Jones, Philip // Diabetes & Primary Care;2013, Vol. 15 Issue 6, p290 

    The author comments on the increased cardiovascular disease risk associated with the use of the glucose-lowering agent sulphonylurea. He believes that formulary developers and prescribing advisors should be aware of the risks of hypoglycaemia prior to prescribing sulphonylureas. He suggests...

  • Case Study--Managing newly diagnosed type-2 diabetes. Bostock-Cox, Beverley // Independent Nurse;6/4/2010, p1 

    The article presents a case study of a 58-year old man, Charlie, who underwent an axillary abscess and was diagnosed as a possible candidate for diabetes. Several changes in his lifestyle and dietary habits for reducing risks of cardiovascular diseases and a continuous monitoring routine were...

  • Metformin Beats Sulfonylurea Drugs at Lowering Mortality among Diabetics.  // Life Extension;Oct2016, p37 

    The article discusses the meta-analysis that found lower risk of dying from cardiovascular disease for diabetics who use metformin compared to those who use sulfonylureas, another class of diabetes drugs, and metformin and sulfonylureas to be more effective at blood glucose reduction.

  • Rosiglitazone CV risk relative to metformin, sulfonylurea.  // Reactions Weekly;7/21/2007, Issue 1161, p5 

    The article discusses research being done on the link between rosiglitazone, metformin, sulfonylurea and cardiovascular (CV) events. The study examined data obtained from the Ingenix Research Database between July 2000 and December 2004 for patients with type 2 diabetes receiving monotherapy...

  • Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality? Rao, Ajay D.; Kuhadiya, Nitesh; Reynolds, Kristi; Fonseca, Vivian A. // Diabetes Care;Aug2008, Vol. 31 Issue 8, p1672 

    OBJECTIVE -- Observational studies assessing the association of combination therapy of metformin and sulfonylurea on all-cause and/or cardiovascular mortality in type 2 diabetes have shown conflicting results. We therefore evaluated the effects of combination therapy of sulfonylureas and...

  • Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir. DAVIES, MELANIE; HELLER, SIMON; SREENAN, SEAMUS; SAPIN, HÉLÈNE; ADETUNJI, OMOLARA; TAHBAZ, ARASH; VORA, JITEN // Diabetes Care;May2013, Vol. 36 Issue 5, p1368 

    OBJECTIVE--This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas). RESEARCH DESIGN AND METHODS--Patients...

  • Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study  // Cardiovascular Diabetology;2011, Vol. 10 Issue 1, p65 

    The article offers information on the research conducted by the authors related to double-blind, randomized, multicentre and active comparator controlled investigation of the effect of pioglitazone, metformin and the combination of both on cardiovascular (CV) risk in patients with type 2...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics